Developmental funds are a major source of flexible funding for the Sidney Kimmel Comprehensive Cancer Center (SKCCC). These funds have allowed the Center to strengthen its scientific programs and provide scientists the opportunity to explore innovative ideas and new collaborations. These funds are critical to maintaining and extending the research vitality of the scientific programs in the SKCCC. Use of these funds is tightly linked to the formal planning and evaluation activifies of the Center. A review of the priority of programmatic needs for new faculty recruitment by the Director, Associate Directors and Program Leaders has resulted in this esfimated allocation of development funds per year during this next CCSG cycle to new faculty investigators $400,000 (66.7%), pilot projects $100,000 (16.6%), and shared resource development $100,000 (16.7%). Funds in the amount of $600,000 in Developmental Funds per year are requested. These funds will be instrumental in achieving the goals of SKCCC's strategic planning. Given the expansion in the SKCCC's research programs and sponsored funding (an increase of over 100% in the last five years), this increase can be justified.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-49
Application #
8559553
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2012-08-09
Budget End
2013-04-30
Support Year
49
Fiscal Year
2012
Total Cost
$457,239
Indirect Cost
$174,993
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Isenberg, Sarina R; Lu, Chunhua; McQuade, John et al. (2017) Impact of a New Palliative Care Program on Health System Finances: An Analysis of the Palliative Care Program Inpatient Unit and Consultations at Johns Hopkins Medical Institutions. J Oncol Pract 13:e421-e430
Husain, Hatim; Velculescu, Victor E (2017) Cancer DNA in the Circulation: The Liquid Biopsy. JAMA 318:1272-1274
Holdhoff, Matthias; Cairncross, Gregory J; Kollmeyer, Thomas M et al. (2017) Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget 8:35523-35531
Oh, Min-Hee; Collins, Samuel L; Sun, Im-Hong et al. (2017) mTORC2 Signaling Selectively Regulates the Generation and Function of Tissue-Resident Peritoneal Macrophages. Cell Rep 20:2439-2454
Klein, Orly R; Buddenbaum, Jessica; Tucker, Noah et al. (2017) Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant 23:325-332
Johnson 3rd, Burles A; Yarchoan, Mark; Lee, Valerie et al. (2017) Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res 23:1656-1669
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2017) Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol 35:2149-2156
Cohen, Joshua D; Javed, Ammar A; Thoburn, Christopher et al. (2017) Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A 114:10202-10207
McCurdy, Shannon R; Kasamon, Yvette L; Kanakry, Christopher G et al. (2017) Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 102:391-400
Isella, Claudio; Brundu, Francesco; Bellomo, Sara E et al. (2017) Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun 8:15107

Showing the most recent 10 out of 2207 publications